{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:26:25Z","timestamp":1782552385746,"version":"3.54.5"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Fund Project of Hebei Health Committee","award":["No.20190459"],"award-info":[{"award-number":["No.20190459"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Chronic kidney disease (CKD) is a progressive and irreversible loss of kidney function. After stage 3, there will be increased risks of hypertension, heart failure, bone disease, anemia, gastrointestinal symptoms, and progression to end-stage kidney failure without proper intervention and treatment. Compound \u03b1-ketoacid tablets (KA) administration plays an important role in clinical CKD adjunctive therapy for patients with restricted protein intake. Bailing Capsule (BC), a commonly used Chinese patent medicine for renal diseases, could regulate human immune function, repair renal tubular epithelial cells, prevent renal tubular atrophy, and reduce kidney damage to improve renal function. In this study, we try to conduct a double-blinded, randomized, controlled trial to observe the efficacy and safety of BC combined with KA in treating patients with stage 3 CKD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This is a double-blinded, randomized, controlled trial. Patients will be randomly divided into treatment group (BC and KT) and control group (BC-simulation and KT) in a 1:1 ratio according to random number table. The treatment course will be 8\u200aweeks, and the changes of subjective symptoms, patient global assessment (PGA) scale, serum creatinine, cystatin C, and estimated glomerular filtration rate, all related adverse events, vital sign measurements, and physical examinations will be recorded. SPSS 21.0 will be used for data analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The results will show whether BC combined with KA could alleviate the symptoms of fatigue, anorexia, halitosis, nausea, itching, and edema, improve kidney function in patients with CKD at stage 3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>OSF Registration number: DOI 10.17605\/OSF.IO\/24AJ7.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025759","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T15:00:27Z","timestamp":1621350027000},"page":"e25759","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Bailing Capsule combined with \u03b1-ketoacid tablets for stage 3 chronic kidney disease"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5488-3588","authenticated-orcid":false,"given":"Xiuhong","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e038423","DOI":"10.1136\/bmjopen-2020-038423","article-title":"Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016 [J]","volume":"10","author":"Hounkpatin","year":"2020","journal-title":"BMJ Open"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12882-020-01966-8","article-title":"Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study [J]","volume":"21","author":"Saminathan","year":"2020","journal-title":"BMC Nephrol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s12882-020-02034-x","article-title":"Prevalence and risk factors for chronic kidney disease of unknown cause in Malawi: a cross-sectional analysis in a rural and urban population [J]","volume":"21","author":"Hamilton","year":"2020","journal-title":"BMC Nephrol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/M20-5938","article-title":"Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO Clinical Practice Guideline [J]","volume":"174","author":"Navaneethan","year":"2021","journal-title":"Ann Intern Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e2023663","DOI":"10.1001\/jamanetworkopen.2020.23663","article-title":"Association of chronic condition special needs plan with hospitalization and mortality among patients with end-stage kidney disease [j]","volume":"3","author":"Becker","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s13300-020-00970-3","article-title":"The treatment effectiveness evaluation for slowing the progression of diabetic nephropathy during stage 4 chronic kidney disease [j]","volume":"12","author":"Yu","year":"2021","journal-title":"Diabetes Ther"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"124","DOI":"10.23876\/j.krcp.19.006","article-title":"Very low protein plus ketoacid analogs of essential aminoacids do not confirm superiority of a low protein diet to retard chronic kidney disease progression [J]","volume":"38","author":"Bolasco","year":"2019","journal-title":"Kidney Res Clin Pract"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3390\/nu11092071","article-title":"Ketoacid analogues supplementation in chronic kidney disease and future perspectives [J]","volume":"11","author":"Koppe","year":"2019","journal-title":"Nutrients"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3760\/cma.j.issn.0366-6999.20130483","article-title":"Effects of Bailing capsules for renal transplant recipients: a retrospective clinical study [J]","volume":"126","author":"Wang","year":"2013","journal-title":"Chin Med J"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3892\/mmr.2020.11293","article-title":"Effectiveness of Bailing capsules in the treatment of lupus nephritis: a meta-analysis [J]","volume":"22","author":"Li","year":"2020","journal-title":"Mol Med Rep"},{"key":"R11-20250504","first-page":"561","article-title":"[Effects of Corbrin Shugan capsule on dimethylnitrosamine-induced hepatic fibrosis in rats] [J]","volume":"42","author":"Qian","year":"2013","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1360386","DOI":"10.1155\/2016\/1360386","article-title":"Dual-directional immunomodulatory effects of corbrin capsule on autoimmune thyroid diseases [J]","volume":"2016","author":"He","year":"2016","journal-title":"Evid Based Complement Alternat Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"109646","DOI":"10.1016\/j.biopha.2019.109646","article-title":"Protective effects of Corbrin Capsule against permanent cerebral ischemia in mice [J]","volume":"121","author":"Wu","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.21037\/apm-20-1799","article-title":"Efficacy and safety of Bailing capsules in the treatment of type 2 diabetic nephropathy: a meta-analysis [J]","volume":"9","author":"Sheng","year":"2020","journal-title":"Ann Palliat Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.21037\/apm-20-1252","article-title":"A meta-analysis of the clinical efficacy and safety of Bailing capsules in the treatment of nephrotic syndrome [J]","volume":"9","author":"Xu","year":"2020","journal-title":"Ann Palliat Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-019-1856-9","article-title":"Compound alpha-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways [J]","volume":"17","author":"Wang","year":"2019","journal-title":"J Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:21:30Z","timestamp":1746339690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025759"}},"subtitle":["Protocol of a double-blinded, randomized, controlled trial"],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":16,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025759","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"2021-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}